TEK and metastatic colorectal cancer: In this research, we analyzed the prognostic and predictive roles of three potential serum biomarkers (Cyclophilin A (CypA), copeptin and Tie2) in 56 patients with metastatic colorectal cancer treated with bevacizumab and chemotherapy.